Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751908 | 0.82 | ALDH1A1 (0.50) | LMNAALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL24045827 | 0.74 | SIGMAR1 (0.58) | LMNAALDH1A1KMT2AMEN1POLB | |
| SCHEMBL23279497 | 0.73 | KMT2A (0.53) | LMNAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL26025885 | 0.71 | POLB (0.47) | ALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL3778246 | 0.70 | LMNA (0.71) | LMNAALDH1A1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL6751695 | 0.70 | CA12 (0.35) | LMNAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL19508166 | 0.69 | HPGD (0.45) | LMNAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL27045359 | 0.67 | KMT2A (0.46) | ALDH1A1TSHRKMT2AMEN1GAA | |
| SCHEMBL17654800 | 0.67 | CA1 (0.42) | LMNAALDH1A1KMT2AMEN1POLB | |
| SCHEMBL28781903 | 0.67 | ALDH1A1 (0.59) | LMNAALDH1A1TSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | CHATTOPADHYAYA JYOTI (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1332150-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | Chattopadhyaya, Jyoti (SE) | 2003-08-06 | — | — | EP | claimed |
| WO-2002038578-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | CHATTOPADHYAYA JYOTI (SE) | 2002-05-16 | — | — | WO | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | RNASEH1, RNASEL, NSUN2 | PRKDC 1041/4885LMNA 384/4885ALDH1A1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.